First SPAC focused on biopharma products launches in Europe
A special purpose acquisition company (SPAC) focused on absorbing companies that make medicines for the biotech and pharmaceutical industry has launched in Europe.
The ‘blank cheque’ company, named eureKING, plans to raise €150 million to buy several contract development and manufacturing organisations (CDMOs) involved in the manufacture of biopharmaceutical products, such as cell and gene therapies.
It intends to list on Euronext Paris and has reportedly identified up to 40 potential CDMO targets so far.
As a SPAC, eureKING is a publicly listed shell company that raises funds to merge with a private company, taking it public without the scrutiny that comes with a traditional IPO.
According to eureKING co-founder and CEO Michael Kloss, the company aims to unite ‘some of the most innovative European players in biomanufacturing to compete with the leading international companies and CDMOs’.
He said: ‘Biotherapies and technological innovations from biopharmaceutical companies are destined to become key products in the treatment of many serious diseases for which no medical solution exists today.
‘These innovations, and especially companies wishing to develop new treatments using these promising technologies, need to benefit from efficient and almost immediate logistical and industrial support, capable of providing them with the tools and production capacity necessary to pursue their clinical developments or to market their products.’
According to Kloss, the company plans to acquire three CDMOs that each make about €50 million in annual revenue over the next few years.
eureKING will target CDMOs in three ‘high growth’ segments: biologics, cell and gene therapy, and live biotherapeutics. On its official website, the company describes the biomanufacturing industry in Europe as ‘booming yet highly fragmented’ and says it plans to ‘act on well identified targets allowing a timely and successful execution of the investment strategy’.
The company’s management team is comprised of Stefan Berchtold, Chief Financial Officer, and Peter Eckenberg, Chief Transformation and Strategy Officer, alongside CEO Michael Kloss. Its co-founders include former Sanofi CEO Gerard Le Fur and Hubert Olivier, President and CEO of McKesson France and Belgium. Its corporate sponsor is eureKARE.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance